Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699554 | 0.90 | LMNA (0.36) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL1699553 | 0.90 | LMNA (0.36) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL1699298 | 0.90 | LMNA (0.36) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL15093184 | 0.89 | LMNA (0.33) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL15093488 | 0.83 | HSD11B1 (0.32) | LMNASMN1; SMN2 | |
| SCHEMBL15153899 | 0.82 | KDM4E (0.37) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL15153900 | 0.82 | KDM4E (0.37) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL1699686 | 0.82 | KDM4E (0.37) | LMNASMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL1699451 | 0.77 | NPC1 (0.36) | LMNAKDM4EALDH1A1GLAKMT2A | |
| SCHEMBL15153915 | 0.77 | NPC1 (0.36) | LMNAKDM4EALDH1A1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | LMNA 2505/4885SMN1; SMN2 2614/4885KDM4E 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.